Scope International Italy is proud to announce the partnership with Assolombarda Confindustria Milano, Monza e Brianza, Lodi, the largest territorial entrepreneurial association in Italy. In particular, SCOPE has joined the pharmaceutical companies group and the “Filiera” Life Sciences. The Filiera provides a framework in which all the companies associated with Assolombarda that are working in the Life Sciences industry in Lombardy have the opportunity to interact with each other.
Through this synergy, SCOPE will increase its visibility in Italy, particularly in Lombardy and extend its network to even more Scientific Research Institutes, investigators and research scientists. This unique network guarantees a faster study start up and provides customers with an excellent consultation through study investigators.
Taking new opportunities
Approximately 6.000 firms, including many life sciences companies, are associated with Assolombarda. It is the most important association within the Confindustria system, the Italian Entrepreneurial Association.
Due to its outstanding organizational efficiency, its excellence and its high-quality standards in the management of clinical studies, SCOPE fits perfectly in the Association´s context. With its accession, SCOPE will make a profound contribution to the work and objectives of Assolombarda Confindustria. By joining different working groups, SCOPE will help promote projects to strengthen the life sciences industry and community and further enhance clinical research in Lombardy.
Scientific excellence concentrated in one region
For Scope, the Lombardy region is of special interest, since it is known for its high amount of pharmaceutical companies and experienced clinical sites. In 2012, clinical trials on pharmaceutical products in Lombardy represented 56,5% of the total Italian ones, mainly concentrated in Phase II and III. In Lombardy, there are currently 18 Scientific Research Institutes (IRCCS) that provide healthcare services to patients, conduct advanced research and promote clinical trials. Lombardy IRCCS represent 37% of the overall IRCCS operating in Italy.
This strong and unique network provides a great opportunity for SCOPE to get in touch with pharmaceutical companies and scientists, to start new collaborations and develop new strategies, ideas and projects. In addition, the close contact with study investigators, research scientists and clinical sites will provide clinical studies with an even more comprehensive support and consultation.